Emcure Pharmas IPO Review
Emcure Pharmaceuticals is limited to raising Rs 4,500 crore – Rs 5,000 crore through an initial public offering, this issue comprises a fresh issue of equity shares worth Rs 1,100 crore and an offer for sale of 18,168,356 shares by its promoter and existing shareholders.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Emcure has ranked as the 12th largest pharmaceutical company in India and the largest pharmaceutical company in India in the gynecology (with 11.85% Indian market share), blood-related (with 10.26% Indian market share), and HIV antiviral therapeutic areas (with 51.43% Indian market share), based on sales in India in the financial year 2021, according to CRISIL. Emcure Pharmaceuticals is an R&D driven company with a differentiated product portfolio that includes orals, injectables, and biologics, as well as an mRNA platform through which the company is currently developing a COVID-19 vaccine that has enabled the company to reach a range of target markets across over 70 countries with a strong presence in Europe and Canada.

Comments
Post a Comment